[1] Blumberg BS, Alter HJ, Visnich S. A ‘new’ antigen in leukemia sera. JAMA,1965,191:541-546.
[2] Blumberg BS, Sutnick A, London WT.Hepatitis and leukemia: their relation to Australia antigen. Bull N Y Acad Med,1968,44:1566-1586.
[3] Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immanoassay. J Virol Methods,2004,115:217-222.
[4] Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev,2000,64:51-68.
[5] Lee HJ, Kim SY, Lee SM, et al. Elecsys hepatitis B surface antigen quantitative assay: performance evaluation and correlation withhepatitis B virus DNA during 96 weeks of follow-up in chronic hepatitis B patients. Ann Lab Med,2012,32:420-425.
[6] Thompson AJ, Nguyen T, Iser D, et al.Serum hepatitis B Surface antigen and hepatitis B e antigen titers;disease phase influences correlation with viral load and intrahepatic hepatitis B virusmarkers. Hepatology,2010,51:1933-1944.
[7] Chan HL, Wong Vw, Tse AM, et al.Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol,2007,5:1462-1468.
[8] Brunetto MR. A new role for an old marker,HBsAg. J Hepatol,2010,52:475-477.
[9] Zhou B, Liu M, Lv G, et al. Quantification of hepatitis B surface antigen and E antigen;correlation between Elecsys and Architect assays. J Viral Hepat,2013,20:422-429.
[10] Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels; association with 5-year response to peginterferon alfa-2a in hepatitis B e antigen-negative patients. Hepatol Int,2013,7:88-97.
[11] Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology, 2011, 54:1591-1599.
[12] Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology,2013,58:872-880.
[13] Gheorghita VI, Caruntu FA, Curescu M, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a:a Romanian cohort study. J Gastrointestin Liver Djs,2013,22:27-32.
[14] Iannazzo S, Coco B, Brunetto MR, et al. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week 12 HBV DNA/HBsAg stopping rule:a cost-effectiveness analysis. Antivir Ther,2013,18:623-633.
[15] Sonneveld MJ, Zoutendijk R, Flink HJ, et al. Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response. Clin Infect Dis,2013,56:100-105.
[16] Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology,2013,58:923-931.
[17] Lee MH, Lee da M, Kim SS, et al.Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol,2011,83:1178-1186.
[18] Song JC, Min BY, Kim JW, et al. Pretreatment serum HBsAg to HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol,2011,l7:268-273.
[19] Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients, J Clin Virol,2010,48:22-26.
[20] Cheng PN, Tsai HW, Chiu YC, et al.Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. J Clin Virol,2013,57:323-330.
[21] Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive,e antigen-positive patients. J Hepatol,2013,58:1089-1095.
[22] Seto WK, Wong DK, Fung J, et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One,2012,7:e43087.
[23] Seo SI, Choi HS, Choi BY, et al. Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection;a retrospective cohort study. J Med Virol,2014,86:124-130.
[24] Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology,2012,142:1140-1149.
[25] Tseng TC, Liu CJ, Yang HC, et al. Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in patients With Low Hepatitis B Virus Loads. Hepatology,2013,57:441-450.
[26] Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B:newtrick of old dog. J Gastroenter,2013,48:13-21.
[27] Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol,2013,59:709-716. |
